Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of sirolimus in segmental overgrowth syndrome
2015-005416-15Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in segmental overgrowth syndrome, sponsored by Universitätsklinikum Freiburg. Primary endpoint: Best response of target lesions by MRI. Started Mar 2016; status: completed.
02
Drugs
sirolimus
03
Conditions
segmental overgrowth syndrome
Beyond the preview
Go deeper on 2015-005416-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005416-15.